Let's face it, Celegene was an important market maker for partnering deals. That is why many a biotech (and their investors) lament the day Celegene was acquired by BMS. So what happens now? Will the deal flow void be filled by other companies? If so, which ones?
These are the questions that respected industry reporter and prognosticator, Luke Timmerman, contemplates in this worthwhile article.
"Who Will Be the Next Celgene of Dealmaking?
VCs, Entrepreneurs Size Up Partners"
Download the full article for an inside look at some of the candidates for “most aggressive” in biopharma business development. If you’re lucky, you might be able to schedule a meeting with someone from one of these companies at BioPharm America™, coming up Sept. 11–12 in Boston.